Medivation's Dimebon improves cognitive function in Huntington's disease
This article was originally published in Scrip
Medivation's investigational drug Dimebon, whose most advanced indication is Alzheimer's disease, improves cognitive function in patients with Huntington's disease and is safe and well-tolerated, top-line results from a Phase II trial suggest.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.